Release characteristics of endogenous constituents by exposure of small intestine to modified beta-cyclodextrins
- PMID: 10549863
- DOI: 10.1248/bpb.22.1099
Release characteristics of endogenous constituents by exposure of small intestine to modified beta-cyclodextrins
Abstract
The aim of the present research is to characterize the leakage of intestinal constituents induced by beta-cyclodextrin (beta-CyD) derivatives using an in situ perfusion and an in vitro everted sac. The efficacy of 6-O-alpha-D-glucosyl (G1)- and 6-O-alpha-D-maltosyl (G2)-beta-CyDs as oral carriers was also compared with that of 2-hydroxypropyl-(HP1; average molar degree of substitution, 0.9) and 2,6-di-O-methyl (DM)-beta-CyDs. In the in situ studies, phenol red (PR) penetration and the release profiles of intestinal constituents for G2-beta-CyD were fairly close to those for HP1-beta-CyD. However, the ability of G2-beta-CyD to include cholesterol was greater than that of HP1-beta-CyD. To characterize the release of intestinal constituents induced by modified beta-CyDs, the capability of including cholesterol was held constant between DM- and branched beta-CyDs. The everted sac study showed that the amount of DM-beta-CyD transferred to the serosal side was not significantly different from the branched beta-CyDs. On the serosal side, the amount of cholesterols released was approximately 3 times higher for DM-beta-CyD than for the branched beta-CyDs at 60 min. The cumulative amounts of cholesterols for DM-beta-CyD increased approximately 6 times at 60 min compared with at 30 min, predominating over the leakage (average 2.6-fold) on the mucosal side. In contrast, the exposure of the branched beta-CyDs resulted in an insignificant increase over the period of this experiment. The present study suggests that permeable beta-CyD derivatives play an important role in the leakage of intestinal components. G2-beta-CyD is preferably recommended as a drug solubilizer in oral formulations as well as HP1-beta-CyD, based on the lower release of intestinal constituents.
Similar articles
-
Effect of sugar-modified beta-cyclodextrins on dissolution and absorption characteristics of phenytoin.Biol Pharm Bull. 1999 Mar;22(3):298-304. doi: 10.1248/bpb.22.298. Biol Pharm Bull. 1999. PMID: 10220288
-
Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells.Eur J Pharm Sci. 2009 Oct 8;38(3):249-61. doi: 10.1016/j.ejps.2009.07.010. Epub 2009 Aug 5. Eur J Pharm Sci. 2009. PMID: 19664706
-
Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.J Pharm Sci. 2001 Jun;90(6):690-701. doi: 10.1002/jps.1025. J Pharm Sci. 2001. PMID: 11357172
-
[Development and pharmaceutical evaluation of hydrophobic cyclodextrin derivatives as modified-release drug carriers].Yakugaku Zasshi. 1993 Jun;113(6):425-37. doi: 10.1248/yakushi1947.113.6_425. Yakugaku Zasshi. 1993. PMID: 8355145 Review. Japanese.
-
[Novel approach of cyclodextrin-based pharmaceutical formulation].Yakugaku Zasshi. 2012;132(1):85-105. doi: 10.1248/yakushi.132.85. Yakugaku Zasshi. 2012. PMID: 22214584 Review. Japanese.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials